K-group, Beta, Inc., A Wholly Owned Subsidiary Of Zentalis Pharmaceuticals, Inc

This early-stage study tested a new oral drug called ZN-c3 in adults with advanced solid tumors that had stopped responding to standard treatments. Researchers aimed to find the safest dose and see if the drug shows any signs of fighting cancer. The trial also checked whether tak…

This study tested a new drug called ZN-c3, both by itself and combined with an existing drug (niraparib), for women with advanced ovarian cancer that had stopped responding to platinum chemotherapy. The main goals were to find safe doses and see if the treatments could shrink tum…

This study tested the safety and early effectiveness of a new drug called azenosertib (ZN-c3) when given with an existing chemotherapy drug, gemcitabine. It involved 31 adults and teenagers (12+) whose osteosarcoma (a type of bone cancer) had come back or stopped responding to pr…